NCT01954615View on ClinicalTrials.gov

Single-ascending Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-281959 / ACT-246475 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics
Interventions
DRUG

5 mg ACT-281959 prodrug formulation I (Group A)

DRUG

20 mg ACT-281959 prodrug formulation I (Group B)

DRUG

ACT-281959 prodrug formulation I (Groups C to G doses to be defined)

DRUG

ACT-281959 prodrug formulation II (Group G dose to be defined)

DRUG

ACT-246475 (Group G dose to be defined)

DRUG

Placebo (Groups A to F)

Trial Locations (1)

35000

Biotrial, Rennes

Sponsors
All Listed Sponsors
lead

Idorsia Pharmaceuticals Ltd.

INDUSTRY

NCT01954615 - Single-ascending Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-281959 / ACT-246475 in Healthy Male Subjects | Biotech Hunter | Biotech Hunter